What does the mechanism of semaglutide predict that TRIUMPH-1 did not test?

The case in front of me: semaglutide · TRIUMPH-1.

This is one of those things that everyone repeats and nobody derives.

This matters practically, not just academically, because it changes what I would do next.

What is the causal chain, and where does it stop being established?

Mechanically, start from the receptor and the rest follows: which receptors, in what ratio, with what signalling bias, reached at what concentration.

Receptor desensitisation as a plateau mechanism is plausible and poorly evidenced. GLP-1R internalises on agonist binding and recycles, and biased agonists that internalise less have been argued to sustain signalling better. Whether any of that operates at the timescale of a four-month clinical plateau — against the much simpler explanation that energy expenditure fell with mass — is not established.

The split between delayed gastric emptying and central satiety matters because they have different time courses. Gastric emptying effects show substantial tachyphylaxis over weeks; the central appetite effect does not, or does so much more slowly. That dissociation is the best available explanation for why nausea fades while appetite suppression persists.

Oral semaglutide’s absorption mechanism via SNAC is described in the pharmacokinetic literature, and the ~1 per cent bioavailability figure with high inter- and intra-individual variability is why administration conditions are specified so tightly[1].

Worth noting that receptor pharmacology measured in a transfected cell line is a starting point, not a physiological measurement, and potency ratios do not transfer cleanly in vivo.

The chemistry is the interesting part and it is also the well-documented part. Read the medicinal chemistry papers; they are short and they explain the design.

To be exact about it, two structural interventions do the work: substitution at the DPP-4 cleavage site to stop enzymatic degradation, and a fatty-acid chain to bind serum albumin and create a slowly released reservoir. Remove either and you are back to a compound requiring continuous infusion.

Comparing a 2.4 mg dose of one agonist to a 15 mg dose of another tells you nothing, because the molar potencies at their respective receptors differ, the receptor profiles differ, and the exposure per milligram differs. The only defensible comparison is between clinical outcomes in trials with comparable populations and durations, which is why SURMOUNT-5 exists and why indirect comparisons should be read sceptically.

Oral bioavailability of a 4 kDa peptide is essentially zero without help. Oral semaglutide is co-formulated with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, which raises local gastric pH and transiently increases transcellular permeability in a small area of gastric mucosa. It works, and it delivers roughly one per cent of the dose, which is why the oral tablet strengths are an order of magnitude above the injectable and why fasting and water volume are not optional details.

The limitation here is that almost all of the human mechanistic work is in the licensed agents, so mechanistic claims about the investigational tri-agonists rest on animal and early-phase data.

Structure predicts pharmacokinetics reliably and clinical effect unreliably. Keep the two claims separate.

GLP-1R is a class B G-protein-coupled receptor signalling predominantly through Gs and cyclic AMP, and most of the interesting pharmacology in this class is about where that signalling happens rather than how hard it is driven.

Orforglipron is not a peptide at all, which changes everything downstream: it is orally bioavailable without an absorption enhancer, it has no fasting or water requirement of the same kind, it does not require cold chain, and it cannot be assayed by any of the peptide methods discussed elsewhere on this site.

The structural basis of semaglutide’s pharmacokinetics — Aib-8, the Arg34Lys substitution and the C18 diacid–AEEA linker at Lys26 — is described in the original medicinal chemistry publication, and it is worth reading once because it makes the design logic explicit[1].

If you want to reason about a new agent, start from its receptor profile and its half-life. Almost everything else follows.

The mechanism question has a clean answer for the peripheral effects and a much less clean answer for the central ones, and it is worth being explicit about which of those you are asking about.

The Aib substitution at position 8 replaces alanine with α-aminoisobutyric acid, which is sterically hindered enough that dipeptidyl peptidase-4 cannot cleave the N-terminal dipeptide. That single change takes the half-life from minutes to hours. The C18 diacid on a linker at Lys26 then binds albumin reversibly, which both shields the molecule from renal filtration and creates a depot that releases slowly — taking hours to about a week.

One qualification: none of the investigational agents discussed here is approved anywhere, and material supplied for research use is not approved for human use.

The mechanism is settled enough to be useful and unsettled enough to be interesting, which is a reasonable place for a field to be.